Day: July 21, 2020

FORT LAUDERDALE, Fla., July 21, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.A replay of the webcast will be archived on the Motus GI website, www.motusgi.com, for 90 days following the event.About Motus GIMotus GI Holdings, Inc. is a medical technology company, with subsidiaries in...

Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., July 21, 2020 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced it will report second quarter 2020 financial results after the market close on Tuesday, August 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.Please log in approximately...

PETERBOROUGH, CA, July 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Rainmaker Worldwide (OTC:RAKR) announces the appointment of Steve Grasso to the Company’s Advisory Board, effective immediately.Grasso is the Director of Institutional Sales at Stuart Frankel & Co. Inc. and an On Air Market Analyst on CNBC. His achievements in trade has made him a recognized and respected voice across financial markets.Grasso began his career in the early ‘90s on The New York Stock Exchange (NYSE) floor, joining Stuart Frankel & Co. in 1999 as an institutional sales trader. For over 20 years, Grasso has been working with the largest mutual funds, pension funds, insurance companies and hedge funds, providing real-time trading advice and services. Clients are kept informed on changes to policy and regulation as a result of Grasso’s...

50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiatedPrimary endpoint of the planned Phase III part to be 28-day all-cause mortality       JENA, Germany, July 21, 2020 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has decided to continue development with IFX-1 in severe COVID-19 induced pneumonia.  The Company plans to initiate a double-blinded, randomized, placebo-controlled Phase III trial that will be adequately powered for...

This year’s annual symposium coincides with the expected launch of Avicanna Inc’s (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) RHO Phyto™ advanced medical cannabis products, manufactured by MediPharm Labs.In the wake of COVID-19, a virtual format will be used that allows for a broader reach to global patients and the medical community.The symposium will present the evolution of medical cannabis including the Avicanna-led advancements, in collaboration with MediPharm Labs for R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers.Leading experts in R&D and clinical development will discuss the potential therapeutic benefits of medical cannabis to address the importance of working with healthcare practitioners for safe and effective dosing.BARRIE,...

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies....

STAMFORD, Conn., July 21, 2020 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (Nasdaq: EGLE) will report its financial results for the second quarter ended June 30, 2020, after the close of stock market trading on Thursday, August 6, 2020. Members of Eagle Bulk’s senior management team will host a teleconference and webcast at 8:00 a.m. ET on Friday, August 7, 2020 to discuss the results.To participate in the teleconference, investors and analysts are invited to call +1 844-282-4411 in the U.S., or +1 512-900-2336 outside of the U.S., and reference participant code 8968944. A simultaneous webcast of the call, including a slide presentation for interested investors and others, may be accessed by visiting http://www.eagleships.com.A replay will be available following the call from 11:00 AM ET on August 7, 2020 until 11:00 AM ET on August...

In the long-term follow-up study of Zolgensma® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA1,2,3The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to ZolgensmaBiogen continues to advance research in spinal muscular atrophy to address the needs of the community and provide additional data to inform treatment decisionsCAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy...

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies....